The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...

Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...

Given every human being is totally unique, it’s no surprise our bodies often behave in different ways. So, while you should ...

Abbott is working to integrate its newest continuous glucose monitor (CGM) with Beta Bionics’ automated insulin delivery (AID) system. The companies plan to connect Beta Bionics’ iLet Bionic Pancreas ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetesWith a single sensor, the ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

Abbott (NYSE: ABT) today announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a prescription. The Lingo system includes a biosensor and a ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...